Agostini M, Schoenmakers E, Beig J, et al. A Pharmacogenetic Approach to the Treatment of Patients With Mutations. Diabetes. 2018;67(6):1086-1092. doi:10.2337/db17-1236
Merino J, Florez JC. Precision medicine in diabetes: an opportunity for clinical translation. Ann N Y Acad Sci. 2018;1411(1):140-152. doi:10.1111/nyas.13588
Latva-Rasku A, Honka MJ, Stančáková A, et al. A Partial Loss-of-Function Variant in Is Associated With Reduced Insulin-Mediated Glucose Uptake in Multiple Insulin-Sensitive Tissues: A Genotype-Based Callback Positron Emission Tomography Study. Diabetes. 2018;67(2):334-342. doi:10.2337/db17-1142
Emdin CA, Klarin D, Natarajan P, et al. Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease. Diabetes. 2017;66(8):2310-2315. doi:10.2337/db17-0149
Sharabi K, Lin H, Tavares CDJ, et al. Selective Chemical Inhibition of PGC-1α Gluconeogenic Activity Ameliorates Type 2 Diabetes. Cell. 2017;169(1):148-160.e15. doi:10.1016/j.cell.2017.03.001
Song R. Mechanism of Metformin: A Tale of Two Sites. Diabetes Care. 2016;39(2):187-9. doi:10.2337/dci15-0013
Chou DHC, Bodycombe NE, Carrinski HA, et al. Small-Molecule Suppressors of Cytokine-Induced beta-Cell Apoptosis. ACS Chem Biol. 2010;5(8):729-34. doi:10.1021/cb100129d
Lundh M, Scully SS, Mandrup-Poulsen T, Wagner BK. Small-molecule inhibition of inflammatory β-cell death. Diabetes Obes Metab. 2013;15 Suppl 3:176-84. doi:10.1111/dom.12158
Vetere A, Choudhary A, Burns SM, Wagner BK. Targeting the pancreatic β-cell to treat diabetes. Nat Rev Drug Discov. 2014;13(4):278-89. doi:10.1038/nrd4231
Maianti JP, McFedries A, Foda ZH, et al. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature. 2014;511(7507):94-8. doi:10.1038/nature13297